Q-Line Biotech IPO
Trading • ₹214.48 Cr
High risk because:
- 5 material risk factors disclosed in DRHP
- Regulatory or legal risks cited in DRHP
- SME listing with thinner post-listing liquidity
IPOFins risk score from DRHP risk factors, subscription demand & issue structure
Price Band
₹343
Lot Size
400 shares
Issue Size
₹214.48 Cr
Open
21 May 2026
Close
25 May 2026
Subscription
88.3×
IPO Schedule
| Issue Open Date | 21 May 2026 |
| Issue Close Date | 25 May 2026 |
| Listing Date | 28 May 2026 |
About Q-Line Biotech
Q-Line Biotech Limited is engaged in the development, manufacturing, and marketing of diagnostic reagents, consumables, and in-vitro diagnostic (IVD) equipment for healthcare and diagnostic applications. The company supplies products such as clinical chemistry reagents, haematology and immunodiagnostic products, molecular diagnostic kits, rapid test kits, point-of-care devices, analysers, laboratory consumables, and diagnostic instruments to diagnostic laboratories, hospitals, and medical colleges. It also provides annual maintenance and after-sales services for medical equipment. During the Covid-19 pandemic, the company developed products including RT-PCR kits, RNA extraction kits, and VTM kits. Q-Line Biotech operates multiple manufacturing facilities, warehouses, and offices in Lucknow, Uttar Pradesh, Delhi, Kolkata and Bhubaneswar. Its manufacturing operations include indigenous production of reagents and diagnostic analysers, while some products are manufactured under technical collaborations with international companies.
Company Details
Founders / Promoters
Mr Saurabh Garg
Founded
2010
Registrar
PURVA
Documents
DRHP / RHP Document (PDF)
View official prospectus →
Investment Analysis
Q-Line Biotech — IPOFins Verdict
QuantitativeDriven by QIB demand at 109.3x and elevated disclosed risk (7/10), Q-Line Biotech listed at a premium of 31.8% to its issue price. SME listings are also thinner and more volatile after listing. The signals lean constructive — still confirm valuation against listed peers and read the DRHP before applying beyond one lot.
- Q-Line Biotech claims to have established manufacturing and R&D capabilities in the in-vitro diagnostics (IVD) segment. The company operates four manufacturing facilities, including three in Lucknow a
- The company has developed a diversified product portfolio across multiple diagnostic categories. Its offerings include clinical chemistry reagents, haematology reagents, rapid and Elisa kits, molecula
- Q-Line Biotech claims to have expanded its manufacturing infrastructure through additional facilities commissioned in 2026. According to the prospectus, the expansion is expected to increase productio
- The company is ISO 13485:2016 certified for its quality management systems for medical devices at its Lucknow manufacturing facility located at Khasra No. 3105, Amausi, Sarojini Nagar, Lucknow. It als
- Q-Line Biotech claims to have a distribution and service network spread across multiple regions in India. As of March 31, 2026, the company had 283 distributors, 103 sales personnel, and 35 service en
Score breakdown — what drove this verdict
High risk from DRHP → score -0.8
Institutional subscription → score +2.0
Strong retail interest → score +0.5
Actual listing outcome → score +1.5
SME IPOs have lower liquidity after listing → score −0.5
Base score: 5.0 · Final score = base + all factor adjustments, capped 1–10. Full methodology →
IPOFins Score is a quantitative signal from subscription demand, disclosed risk, and listing data — not investment advice. Not SEBI-registered.
Listing Performance
Issue Price
₹343
Listing Price
₹452
Listing Gain/Loss
+31.78%
Listing Date
28 May 2026
Price Since Listing
Returns are measured against the ₹343 issue price.
Listing
₹452
+31.8%
Current
₹508
+48.1%
Want to buy this stock?
Trade Q-Line Biotech on the secondary market
FAQ
What is the price band of Q-Line Biotech IPO?
The price band is ₹343 per share with a lot size of 400 shares. Minimum investment: ₹1,37,200.
What does Q-Line Biotech do?
Q-Line Biotech Limited is engaged in the development, manufacturing, and marketing of diagnostic reagents, consumables, and in-vitro diagnostic (IVD) equipment for healthcare and diagnostic applications. The company supplies products such as clinical chemistry reagents, haematology and immunodiagnostic products, molecular diagnostic kits, rapid test kits, point-of-care devices, analysers, laboratory consumables, and diagnostic instruments to diagnostic laboratories, hospitals, and medical colleges. It also provides annual maintenance and after-sales services for medical equipment. During the Covid-19 pandemic, the company developed products including RT-PCR kits, RNA extraction kits, and VTM kits. Q-Line Biotech operates multiple manufacturing facilities, warehouses, and offices in Lucknow, Uttar Pradesh, Delhi, Kolkata and Bhubaneswar. Its manufacturing operations include indigenous production of reagents and diagnostic analysers, while some products are manufactured under technical collaborations with international companies.
Should I apply for Q-Line Biotech IPO?
Q-Line Biotech listed at ₹452 (+31.8% premium to the ₹343 issue price) after 88.3x subscription. IPOFins Score 8/10: Driven by QIB demand at 109.3x and elevated disclosed risk (7/10), Q-Line Biotech listed at a premium of 31.8% to its issue price. SME listings are also thinner and more volatile after listing. The signals lean constructive — still confirm valuation against listed peers and read the DRHP before applying beyond one lot.
Who founded Q-Line Biotech?
Q-Line Biotech was founded by Mr Saurabh Garg in 2010.